-
-
-
-
-
-
-
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
-
-
-
-
-
-
-
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
-
-
-
-
-
-
-
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
-
-
-
-
-
-
-
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
-
-
-
-
-
-
-
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stres
-
-
-
-
-
-
-
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
-
-
-
-
-
-
-
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

